Flavio Rojas-Castillejos
A5085004921- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Multiple Myeloma Research and Treatments
- Lymphoma Diagnosis and Treatment
- Eosinophilic Disorders and Syndromes
- Kruppel-like factors research
- Peptidase Inhibition and Analysis
- Hemophilia Treatment and Research
- Hemoglobinopathies and Related Disorders
- Blood groups and transfusion
- Acute Lymphoblastic Leukemia research
- Platelet Disorders and Treatments
- Hematological disorders and diagnostics
- Ethics and bioethics in healthcare
- Neutropenia and Cancer Infections
- Diabetes Management and Research
- Metabolism, Diabetes, and Cancer
- Cancer Diagnosis and Treatment
- Cultural, Media, and Literary Studies
- Cancer Genomics and Diagnostics
- Hemostasis and retained surgical items
- Medical Malpractice and Liability Issues
- Blood disorders and treatments
- Protein Degradation and Inhibitors
Hospital General De Zona
2023
Mexican Social Security Institute
2023
Institute for Social Security and Services for State Workers
2021-2022
Hospital de Especialidades
2020-2022
Acute myeloid leukemia (AML) comprises a heterogeneous group of hematopoietic cell neoplasms lineage that arise from the clonal expansion their precursors in bone marrow, interfering with differentiation, leading to syndrome marrow failure. AML is consequence genetic and epigenetic changes (point mutations, gene rearrangements, deletions, amplifications, arrangements influence expression) precursor cells, which create clone abnormal cells are capable proliferating but cannot differentiate...
Para identificar una patología cada vez más común, conocida como mieloma múltiple, es necesario hacer alusión de los factores específicos que la caracterizan. ello existen clásicos criterios conocidos CRAB (hipercalcemia, insuficiencia renal, anemia y lesiones líticas), siendo renal sus complicaciones frecuentes. Recientemente se han descrito tres biomarcadores indiscutibles para el apoyo diagnóstico del son: 10% células plasmáticas clonales en medula ósea o biopsia corrobora presencia un...
Myelofibrosis (MF) is a BCR-ABL1-negative myeloproliferative neoplasm characterized by clonal myeloproliferation, dysregulated kinase signaling, and release of abnormal cytokines. In recent years, important progress has been made in the knowledge molecular biology prognostic assessment MF. Conventional treatment limited impact on patients' survival; it includes wait-and-see approach for asymptomatic patients, erythropoiesis-stimulating agents, androgens, or immunomodulatory agents anemia,...
Essential thrombocythemia (ET) is a chronic Philadelphia-negative myeloproliferative neoplasm that has its main involvement in the megakaryopoietic lineage, generating sustained thrombocytosis peripheral blood and an increase number of mature megakaryocytes bone marrow. In addition to marked thrombocytosis, it characterized by increased thrombotic or hemorrhagic risk presence constitutional symptoms. Patients with ET have low but known disease progression myelofibrosis and/or acute leukemia....
Hemophilia is a hemorrhagic disorder with sex-linked inherited pattern, characterized by an inability to amplify coagulation due deficiency in factor VIII (hemophilia A or classic) IX B).Sequencing of the genes involved hemophilia has provided description and record main mutations, as well correlation various degrees severity.Hemorrhagic manifestations are related levels circulating factor, mainly affecting musculoskeletal system specifically large joints (knees, ankles, elbows).This...
Hemophilia is a hemorrhagic disorder with sex-linked inherited pattern, characterized by an inability to amplify coagulation due deficiency in factor VIII (hemophilia A or classic) IX B). Sequencing of the genes involved hemophilia has provided description and record main mutations, as well correlation various degrees severity. Hemorrhagic manifestations are related levels circulating factor, mainly affecting musculoskeletal system specifically large joints (knees, ankles, elbows). This...
To identify this increasingly common pathology, known as multiple myeloma (MM), it is necessary to refer the specific factors that characterize it; end, classic criteria CRAB (hyperkalemia, renal failure, anemia, and lytic lesions) are available, in which failure one of most frequent complications.Recently, three indisputable biomarkers have been described for diagnostic support MM, are: more than 10% clonal plasma cells bone marrow or, a biopsy corroborates presence plasmacytoma, light...
Acute myeloid leukemia (AML) comprises a heterogeneous group of hematopoietic cell neoplasms lineage that arise from the clonal expansion their precursors in bone marrow, interfering with differentiation, leading to syndrome marrow failure.AML is consequence genetic and epigenetic changes (point mutations, gene rearrangements, deletions, amplifications, arrangements influence expression) precursor cells, which create clone abnormal cells are capable proliferating but cannot differentiate...
Hodgkin's lymphoma (HL) is due to the clonal transformation of cells originating from B lymphocytes, generating pathognomonic binucleate Reed-Sternberg cells.HL a cell disease with bimodal distribution, higher incidence in adolescence and third decade life, showing second peak people over 55 years age.Classic Hodgkin routinely undergo gene expression reprogramming, as they lose most typical B-cell genes acquire multiple that are other types immune system.The treatment algorithm will
El linfoma de Hodgkin (LH) se debe a la transformación clonal células originadas en los linfocitos B, lo que genera las binucleadas patognomónicas Reed-Sternberg. LH es una enfermedad B con distribución bimodal, mayor incidencia adolescencia y tercera década vida un segundo pico personas mayores 55 años. Las del clásico habitualmente sufren reprogramación expresión génica, ya pierden mayoría genes típicos han adquirido múltiples son otros tipos sistema inmunitario. algoritmo tratamiento...
El objetivo de este trabajo es generar recomendaciones sobre el manejo del trasplante alogénico células madre (alo-SCT) en la mielofibrosis primaria (MFP). Se utilizó una revisión sistemática integral artículos publicados entre 1999 y 2015 (enero) como fuente evidencia científica. Las se produjeron mediante un proceso Delphi que participó panel 23 expertos designados por European LeukemiaNet Blood and Marrow Transplantation Group. preguntas clave incluyeron selección pacientes, donantes,...
La trombocitemia esencial (TE) es una neoplasia mieloproliferativa crónica Filadelfia negativa que tiene su principal involucro en la línea megacariopoyética, generando trombocitosis sostenida sangre periférica y un incremento el número de megacariocitos maduros médula ósea. Además marcada trombocitosis, se caracteriza por mayor riesgo trombótico o hemorrágico presencia síntomas constitucionales. Los pacientes con TE tienen bajo, pero conocido, evolución enfermedad a mielofibrosis y/o...
Además de la sintomatología secundaria a esplenomegalia, las alteraciones microvasculares y complicaciones trombohemorrágicas, los pacientes con neoplasias mieloproliferativas (NMP) pueden experimentar una importante carga sintomática atribuida un aumento citocinas inflamatorias circulantes. Estos síntomas ser severos limitar calidad vida. Por ello, además prevención complicaciones, uno objetivos del tratamiento NMP es el control síntomas.
Las neoplasias mieloproliferativas (NMP) están asociadas a un riesgo notable de trombosis y el entorno hipercoagulabilidad propio del embarazo aumenta este riesgo. complicaciones gestacionales más frecuentes consisten en: aborto espontáneo, trombosis, sangrado enfermedad hipertensiva embarazo. El tratamiento depende trombótico, trimestre gestacional neoplasia mieloproliferativa.
Los pacientes con neoplasias mieloproliferativas tienen un riesgo incrementado de trombosis y sangrado. Se debe identificar dicho riesgo, así como individualizar la estrategia terapéutica previo a los procedimientos invasivos; una adecuada citorreducción disminuye el complicaciones.
La mielofibrosis (MF) es una neoplasia mieloproliferativa negativa para BCR-ABL1 caracterizada por mieloproliferación clonal, señalización de cinasa desregulada y liberación citocinas anormales. En los últimos años se han realizado importantes avances en el conocimiento la biología molecular valoración pronóstica MF. El tratamiento convencional tiene un impacto limitado supervivencia pacientes; incluye enfoque espera pacientes asintomáticos, agentes estimulantes eritropoyesis, andrógenos o...
In addition to symptoms secondary splenomegaly, microvascular abnormalities, and thrombohemorrhagic complications, patients with MPN may experience a significant symptom burden attributed an increase in circulating inflammatory cytokines. These can be severe limit quality of life. Therefore, the prevention one objectives treatment is control symptoms.Además de la sintomatología secundaria esplenomegalia, las alteraciones microvasculares y complicaciones trombohemorrágicas, los pacientes con...
Myeloproliferative neoplasms (MPN) are associated with a significant risk of thrombosis and the hypercoagulable environment pregnancy increases this risk. The most frequent gestational complications consist spontaneous abortion, thrombosis, bleeding, hypertensive disease pregnancy. Treatment depends on thrombotic risk, trimester, myeloproliferative neoplasm.
Polycythemia vera (PV) is mainly characterized by erythrocytosis, thrombotic and hemorrhagic predisposition, a variety of symptoms, cumulative risks fibrotic progression and/or leukemic evolution over time. The diagnosis made based on the 2016 WHO criteria. treatment PV focuses rapidly reducing erythrocyte mass, either means phlebotomies or with cytoreductive treatment, reduction risk correcting cardiovascular factors use platelet antiaggregants.
Major thrombotic complications in myeloproliferative neoplasms (MPNs) represent an important clinical problem due to their high morbidity, the complexity of management, and associated mortality. The appearance a thrombosis implies risk stratification MPN determines initiation or optimization cytoreductive treatment use antiplatelet anticoagulant therapy as secondary prophylaxis. incidence at time diagnosis is higher than during course disease, being located arterial territory 60-70% cases....
Patients with myeloproliferative neoplasms have an increased risk of thrombosis and bleeding. This must be identified, as well individualizing the therapeutic strategy before invasive procedures; adequate cytoreduction reduces complications.Los pacientes con neoplasias mieloproliferativas tienen un riesgo incrementado de trombosis y sangrado. Se debe identificar dicho riesgo, así como individualizar la estrategia terapéutica previo a los procedimientos invasivos; una adecuada citorreducción...
La policitemia vera (PV) se caracteriza principalmente por eritrocitosis, predisposición trombótica y hemorrágica, una variedad de síntomas riesgos acumulativos progresión fibrótica y/o evolución leucémica a lo largo del tiempo. El diagnóstico realiza con base en los criterios la Organización Mundial Salud 2016. tratamiento PV centra reducir rápidamente masa eritrocitaria, ya sea medio flebotomías o citorreductor, disminución riesgo trombótico mediante corrección factores cardiovascular el...